387 results match your criteria: ""S.G.Moscati" Hospital[Affiliation]"
Eur J Cancer Care (Engl)
November 2022
Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy.
Objective: The primary goal of the Campania Oncology Network (ROC) was to reduce cancer delay and care fragmentation through the establishment of cancer-specific multidisciplinary oncologic groups (GOMs) and diagnostic and therapeutic assistance paths (PDTAs).
Methods: Five cancer centres of the ROC, with their own cancer specific GOM, were selected. In our analysis, we have focused on four neoplasms: lung, colon, ovarian and prostate cancers.
Front Pharmacol
March 2023
Division of Hematology, Department of Precision and Translational, Policlinico Umberto 1, Sapienza University, Rome, Italy.
TKIs long-term treatment in CML may lead to persistent adverse events (AEs) that can promote relevant morbidity and mortality. Consequently, TKIs dose reduction is often used to prevent AEs. However, data on its impact on successful treatment-free remission (TFR) are quite scarce.
View Article and Find Full Text PDFCancers (Basel)
March 2023
Pathology Unit, Azienda Ospedaliera Santa Maria di Terni, University of Perugia, 05100 Terni, Italy.
Mast cell leukemia (MCL) is the leukemic form of SM with at least 20% mostly immature mast cells on bone marrow aspirate. MCL may develop de novo, in the absence of a prior SM, or it may represent a progression from a previous SM. MCL may be sub-divided into the more frequent, aggressive acute form with signs of organ damage (C-findings) and the chronic form lacking C-findings and presenting a more stable course, although over time, progression to acute MCL is common.
View Article and Find Full Text PDFESMO Open
April 2023
Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
Background: The use of immune checkpoint inhibitors (ICIs) in the front-line treatment of advanced non-small-cell lung cancer (NSCLC) is currently the standard of care. However, as clinical trials include a very limited number of elderly patients, evidence on the safety and efficacy of using ICI-based regimens is still limited.
Methods: A virtual International Expert Panel took place in July 2022 to review the available evidence on the use of ICI-based regimens in the first-line setting in elderly patients with NSCLC and provide a position paper on the field both in clinical practice and in a research setting.
Expert Opin Biol Ther
March 2023
Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy.
Int J Mol Sci
January 2023
Division of Medical Oncology, 'S.G. Moscati' Hospital, 83100 Avellino, Italy.
RET-selective tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib have revolutionized the landscape of RET-positive (RET+) advanced non-small cell lung cancer (NSCLC) treatment, thanks to their efficacy and safety profiles. This class of medications currently represents the standard of care for both naïve and patients that have not received selective RET-TKIs in the first-line setting. However, we presently lack a satisfactory understanding of resistance mechanism developing after selective RET-TKIs usage, as well as a specific treatment for patients progressing on selpercatinib or pralsetinib.
View Article and Find Full Text PDFInt J Mol Sci
January 2023
Department of Medicine and Health Sciences "V. Tiberio", University of Molise, Via F. De Sanctis, 86100 Campobasso, Italy.
In the present paper, a simple method for analyzing the self-aggregation of dyes in a solution by a UV-visible absorption measurements is proposed. The concept of excess absorbance is introduced to determine an equation whose coefficients determine the parameters of the aggregation equilibrium. The computational peculiarities of the model are first discussed theoretically and then applied to sodium fluorescein in polar protic and aprotic solvents, as well as in aqueous solutions of methylene blue, which is a cationic dye.
View Article and Find Full Text PDFCancer Drug Resist
November 2022
Division of Medical Oncology, "S.G. Moscati" Hospital, Avellino 83100, Italy.
Ann Transl Med
November 2022
Department of Pharmacy, Zengchen District People's Hospital of Guangzhou (Boji-Affiliated Hospital of Sun Yat-sen University), Guangzhou, China.
Background: Nivolumab is the first programmed cell death receptor 1 (PD-1) inhibitor approved in China. Compared with chemotherapy, nivolumab has shown advantages of good efficacy and safety in the treatment of a variety of tumors. However, due to its short time of use in China and lack of safety experience, clinical understanding of its adverse reactions has not been sufficiently elucidated.
View Article and Find Full Text PDFAorta (Stamford)
December 2022
Division of Cardiac Surgery, Department of Cardiovascular Surgery, S.G. Moscati Hospital, Avellino, Italy.
A 61-year-old man presented to our institution complaining of back pain. Breathing was comfortable. An arterial blood gas showed extreme hypoxia causing chronic respiratory alkalosis.
View Article and Find Full Text PDFThromb Res
December 2022
Thrombosis Center, 'Careggi' Hospital, Florence, Italy.
Orthop Rev (Pavia)
October 2022
Department of Orthopedics and Traumatology , "S. G. Moscati" Hospital - Aversa (CE) - Italy.
Periprosthetic fractures around total knee arthroplasty in elderly represent an emerging cause of implant revision and their incidence seems destined to further increase in the upcoming years, considering the ever-increasing number of implanted prostheses. These are complex injuries with very high complication rates. It has been estimated that the incidence of femoral periprosthetic fractures after T.
View Article and Find Full Text PDFLeuk Res
November 2022
Division of Hematology and Bone Marrow Transplantation, Azienda Sanitaria Universitaria Integrata Friuli Centrale (ASUFC), Udine, Italy.
Clin Lung Cancer
December 2022
Department of Medicine, Division of Medical Oncology, University of Colorado Cancer Center, Aurora, CO.
Background: Brigatinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor with demonstrated efficacy in locally advanced and metastatic non-small cell lung cancer (NSCLC) in crizotinib-refractory and ALK inhibitor-naive settings. This analysis assessed brigatinib in Asian vs. non-Asian patients from the first-line ALTA-1L trial.
View Article and Find Full Text PDFJ Hazard Mater
September 2022
Department of Medicine, Surgery and Dentistry "Schola Medica Salernitana", University of Salerno, Baronissi, Italy. Electronic address:
Transl Lung Cancer Res
July 2022
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Int J Mol Sci
August 2022
Department of Public Health, University of Naples Federico II, 80131 Naples, Italy.
Front Oncol
July 2022
European Institute of Oncology, IRCCS, Division of Thoracic Surgery, Milan, Italy.
J Neurol
November 2022
Center for Neurodegenerative Diseases (CEMAND), Department of Medicine, Surgery and Odontology "Scuola Medica Salernitana", University of Salerno, Salerno, Italy.
Introduction: Progranulin (PGRN) is a secreted glycoprotein encoded in humans by the GRN gene, located on chromosome 17q21. Several nonsense and missense pathogenetic GRN mutations have been described.
Objective: We herein describe two sisters carrying a rare GRN mutation with extremely different clinical features and family history of dementia and behavioral disorders, with a novel presentation with stridor and dysphonia.
Transl Lung Cancer Res
June 2022
Division of Medical Oncology, 'S. G. Moscati' Hospital, Avellino, Italy.
J Thorac Dis
June 2022
Division of Medical Oncology, 'S. G. Moscati' Hospital, Avellino, Italy.
Per Med
September 2022
Department of Public Health, University of Naples Federico II, Naples, Italy.
, , and gene fusions and exon 14 skipping alterations represent novel predictive biomarkers for advanced non-small-cell lung cancer (NSCLC). Therefore, testing patients for these genetic variants is crucial for choosing the best selective treatment. Over the last couple of decades, next-generation sequencing (NGS) platforms have emerged as an extremely useful tool for detecting these variants.
View Article and Find Full Text PDFLife (Basel)
May 2022
Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Napoli, Italy.
In recent years, stereotactic body radiation therapy (SBRT) has gained popularity among clinical methods for the treatment of medium and low risk prostate cancer (PCa), mainly as an alternative to surgery. The hypo-fractionated regimen allows the administration of high doses of radiation in a small number of fractions; such a fractionation is possible by exploiting the different intrinsic prostate radiosensitivity compared with the surrounding healthy tissues. In addition, SBRT treatment guaranteed a better quality of life compared with surgery, avoiding risks, aftermaths, and possible complications.
View Article and Find Full Text PDFHematol Oncol
October 2022
Hematology Unit, Azienda Ospedaliera of Cosenza, Cosenza, Italy.
The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers.
View Article and Find Full Text PDFIn infants and children, fever is very common in the emergency setting. The overall aim of the present publication was to overview guidance and provide an algorithm for use in the emergency setting as well as recommendations to inform parents for home care. To obtain consensus, a core steering committee drafted a management algorithm and general consensus was obtained by remote voting among experts.
View Article and Find Full Text PDF